Standardizing Patient-Reported Outcomes Assessment in Cancer Clinical Trials: A Patient-Reported Outcomes Measurement Information System Initiative
Top Cited Papers
- 10 November 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (32) , 5106-5112
- https://doi.org/10.1200/jco.2007.12.2341
Abstract
Patient-reported outcomes (PROs), such as symptom scales or more broad-based health-related quality-of-life measures, play an important role in oncology clinical trials. They frequently are used to help evaluate cancer treatments, as well as for supportive and palliative oncology care. To be most beneficial, these PROs must be relevant to patients and clinicians, valid, and easily understood and interpreted. The Patient-Reported Outcomes Measurement Information System (PROMIS) Network, part of the National Institutes of Health Roadmap Initiative, aims to improve appreciably how PROs are selected and assessed in clinical research, including clinical trials. PROMIS is establishing a publicly available resource of standardized, accurate, and efficient PRO measures of major self-reported health domains (eg, pain, fatigue, emotional distress, physical function, social function) that are relevant across chronic illnesses including cancer. PROMIS is also developing measures of self-reported health domains specifically targeted to cancer, such as sleep/wake function, sexual function, cognitive function, and the psychosocial impacts of the illness experience (ie, stress response and coping; shifts in self-concept, social interactions, and spirituality). We outline the qualitative and quantitative methods by which PROMIS measures are being developed and adapted for use in clinical oncology research. At the core of this activity is the formation and application of item banks using item response theory modeling. We also present our work in the fatigue domain, including a short-form measure, as a sample of PROMIS methodology and work to date. Plans for future validation and application of PROMIS measures are discussed.Keywords
This publication has 16 references indexed in Scilit:
- Evaluation of Item CandidatesMedical Care, 2007
- Intended and Unintended ConsequencesMedical Care, 2007
- Invited Paper C The use of cognitive interviewing techniques in quality of life and patient-reported outcomes assessmentPublished by Cambridge University Press (CUP) ,2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Feasibility of docetaxel, epirubicin, and capecitabine (TEX) plus pegfilgrastim as neoadjuvant treatment for primary breast cancer: A pilot studJournal of Clinical Oncology, 2004
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS StudyJournal of Clinical Oncology, 2003
- Health-Related Quality-of-Life Assessments and Patient-Physician CommunicationJAMA, 2002
- Methods to Explain the Clinical Significance of Health Status MeasuresMayo Clinic Proceedings, 2002
- Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatientsPsycho‐Oncology, 2000